What's Happening?
Augurex Life Sciences Corp., a company specializing in autoimmune biomarker diagnostics, has been awarded the Immunology Abstract Award at the 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Conference. The award recognizes the company's
scientific abstract on 'Anti-14-3-3eta Autoantibodies,' which serves as a novel diagnostic biomarker capable of distinguishing axial spondyloarthritis from mechanical back pain. This research addresses a significant unmet need in diagnosing inflammatory back pain. The abstract was selected from approximately 800 submissions and will be featured in an ePoster Discussion at the conference. Dr. Anthony Marotta, Chair of Augurex’s Clinical and Scientific Advisory Boards, led the research in collaboration with global experts. The recognition highlights the potential of Augurex's SPINEstat® diagnostic assay to improve the identification of patients with axial spondyloarthritis.
Why It's Important?
The recognition of Augurex's research underscores the importance of developing precise diagnostic tools for autoimmune diseases, which can significantly impact patient care and treatment outcomes. Axial spondyloarthritis is often misdiagnosed as mechanical back pain, leading to delays in appropriate treatment. By providing a reliable biomarker, Augurex's work could reduce diagnostic delays, allowing for earlier and more targeted interventions. This advancement is crucial for patients who suffer from inflammatory back pain, as timely diagnosis can prevent further complications and improve quality of life. The award also highlights the role of innovative diagnostics in advancing clinical practice and laboratory medicine, potentially influencing future research and development in the field.
What's Next?
Dr. Marotta will formally receive the award at the ADLM IID Division Awards Reception and present the research during the IID Division ePoster Discussion. Augurex will also exhibit at the ADLM Clinical Lab Expo, showcasing SPINEstat® as a finalist for the ADLM Disruptive Technology Award. These events provide opportunities for further engagement with the diagnostics community and potential collaborations to advance the application of the SPINEstat® assay. The continued development and validation of this diagnostic tool could lead to its broader adoption in clinical settings, ultimately benefiting patients with axial spondyloarthritis.
